EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mast cell–derived IL-13 as a driver of Crohn disease–associated intestinal fibrosis

Kwestan Safari iD, Wei Jen Ma, Prabhreet Sekhon, Priya Rai, Susan C Menzies, Tomoaki Hoshino, Anne-Sophie Fratzscher, Andrew Roth iD, Karen Madsen, Laura M Sly

Inflammatory Bowel Diseases · 2026

DOI: 10.1093/ibd/izag127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Kwestan Safari und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Gastroenterology, the University of British Columbia and BC Children's Hospital Research Institute, Vancouver, …. Hauptthemen laut MEDLINE: Mast Cells, Interleukin-13, Crohn Disease, Fibrosis. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Crohn disease is a chronic, immune-mediated disease that can lead to intestinal fibrosis, strictures, and bowel obstruction. The Src homology 2 domain-containing inositol polyphosphate 5′-phosphatase-deficient (SHIP−/−) mouse develops spontaneous Crohn disease–like ileal inflammation and fibrosis. Fibrosis depends on increased phosphatidylinositol 3-kinase p110δ activity downstream of interleukin 4 (IL-4) or IL-13. Because current anti-inflammatory treatments do not prevent or reverse fibrosis, we aimed to identify the key cytokine(s) and its cellular source(s).

Methods

We blocked IL-4 or IL-13 in mice by use of neutralizing antibodies or genetic ablation. Intestinal inflammation and fibrosis were assessed by gross pathology, histopathology, collagen accumulation, muscle thickening, immune cell infiltration, and tissue IL-1β concentrations. IL13 and its cellular source in stricturing Crohn disease were examined using single-cell RNA sequencing and RNAscope. Mast cells and Il13 were also assessed in ileal cross-sections from SHIP+/+ and SHIP−/− mice.

Results

Blocking or genetic ablation of IL-13, but not IL-4, significantly reduced ileal fibrosis in mice, including collagen accumulation, smooth muscle thickening, vimentin + cells, and proliferating vimentin + cells. Blockade of IL-13 also reduced intestinal inflammation, including immune cell infiltration and ileal IL-1β concentrations. Single-cell RNA-sequencing analyses identified mast cells as the exclusive source of IL13 in stricturing Crohn disease. Human resection tissues confirmed increased mast cells in diseased small intestine and identified mast cells as the source of IL13. SHIP−/− mice similarly showed increased ileal mast cells that were also a source of IL13.

Conclusions

IL-13 is critical for intestinal fibrosis in SHIP-deficient mice, and mast cells are a source of IL13 in Crohn disease–associated intestinal fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mast CellsInterleukin-13Crohn DiseaseFibrosisAnimalsMiceInterleukin-4Mice, KnockoutHumansPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesDisease Models, AnimalMice, Inbred C57BLMale

Stichwörter der Autor:innen

Crohn disease fibrosisSH2 domain-containing inositol polyphosphate 5'-phosphataseinterleukin-13mast cells

Substanzen

Interleukin-13Interleukin-4Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Gastroenterology, the University of British Columbia and BC Children's Hospital Research Institute, Vancouver, British Columbia, V5Z 4H4, Canada.
  • Department of Internal Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan.
  • Department of Molecular Oncology, the University of British Columbia and British Columbia Cancer Research Centre, Vancouver, British Columbia, V5Z 1L3, Canada.
  • Department of Medicine, and Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR), University of Alberta, Edmonton, Alberta, T6G 2H5, Canada.

ORCID-Profile: Kwestan Safari, Andrew Roth

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Safari, K., Ma, W. J., Sekhon, P., Rai, P., Menzies, S. C., Hoshino, T., Fratzscher, A. S., Roth, A., Madsen, K., & Sly, L. M. (2026). Mast cell–derived IL-13 as a driver of Crohn disease–associated intestinal fibrosis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag127

Vancouver

Safari K, Ma WJ, Sekhon P, Rai P, Menzies SC, Hoshino T, et al. Mast cell–derived IL-13 as a driver of Crohn disease–associated intestinal fibrosis. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag127

BibTeX
@article{Safari2026,
  author = {Safari, Kwestan and Ma, Wei Jen and Sekhon, Prabhreet and Rai, Priya and Menzies, Susan C and Hoshino, Tomoaki and Fratzscher, Anne-Sophie and Roth, Andrew and Madsen, Karen and Sly, Laura M},
  title = {Mast cell–derived IL-13 as a driver of Crohn disease–associated intestinal fibrosis},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izag127}
}
Kostenlos starten →